A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04188379 |
|
Recruitment Status :
Completed
First Posted : December 5, 2019
Last Update Posted : March 7, 2024
|
Sponsor:
argenx
Information provided by (Responsible Party):
argenx
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | February 3, 2022 |
| Actual Study Completion Date : | February 3, 2022 |
| Certification/Extension First Submitted : | February 2, 2023 |